Sugi Predict

Sugi Predict / Compounds / SCHEMBL16514536

SCHEMBL16514536

SCHEMBL16514536

C=CC(=O)Nc1cc(-c2cccc3cnc(Nc4ccc(N5CCN(C)CC5)cc4)nc23)ccn1

nearest known ligand 0.70

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 7/20 0.70
▸ FGFR2 P21802 2/20 0.68
▸ FGFR1 P11362 5/20 0.66
▸ KDR P35968 2/20 0.66
▸ JAK2 O60674 3/20 0.60
▸ BRD4 O60885 1/20 0.60
▸ BTK Q06187 4/20 0.59
▸ JAK3 P52333 5/20 0.57
▸ MAP3K7 O43318 5/20 0.57
▸ MAP2K1 Q02750 3/20 0.57
▸ SRC P12931 3/20 0.56
▸ JAK1 P23458 1/20 0.56
▸ TYK2 P29597 1/20 0.56
▸ MAPK1 P28482 1/20 0.56
▸ BLK P51451 1/20 0.55
▸ BMX P51813 1/20 0.55
▸ FLT3 P36888 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16514873 0.92 EGFR (0.61) EGFRFGFR2FGFR1KDRJAK2
SCHEMBL16515112 0.92 EGFR (0.83) EGFRFGFR2FGFR1KDRJAK2
SCHEMBL16513680 0.91 EGFR (0.66) EGFRFGFR2FGFR1KDRJAK2
SCHEMBL29847832 0.91 EGFR (0.66) EGFRFGFR2FGFR1KDRJAK2
SCHEMBL16514018 0.91 FGFR2 (0.83) EGFRFGFR2FGFR1KDRJAK2
SCHEMBL16514260 0.91 EGFR (0.64) EGFRFGFR2FGFR1KDRJAK2
SCHEMBL16514927 0.90 EGFR (0.65) EGFRFGFR2FGFR1KDRJAK2
SCHEMBL29847016 0.90 EGFR (0.85) EGFRFGFR2FGFR1KDRJAK2
SCHEMBL16514922 0.90 EGFR (0.85) EGFRFGFR2FGFR1KDRJAK2
SCHEMBL16513722 0.90 FGFR2 (0.72) EGFRFGFR2FGFR1KDRJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105682661-B Certain chemical entities, compositions, and methods 润新生物公司 2020-03-27 — — CN claimed
EP-3035936-B1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA INC (US) 2019-03-13 — — EP claimed
US-9849139-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2017-12-26 — — US claimed
US-20170196881-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA, INC. 2017-07-13 — — US claimed
US-9550770-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2017-01-24 — — US claimed
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2015-06-25 — — US claimed
US-20260102406-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA INC (US) 2026-04-16 — — US disclosed
EP-3508204-B1 QUINAZOLIN-8-YL DERIVATIVES FOR USE IN METHODS OF TREATING MELANOMA, NON-SMALL CELL LUNG CANCER, THYROID CANCER, OVARIAN CANCER, OR COLON CANCER NEUPHARMA INC (US) 2026-02-11 — — EP disclosed
US-12403145-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC (US) 2025-09-02 — — US disclosed
US-20240197752-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA INC 2024-06-20 — — US disclosed
US-11865120-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2024-01-09 — — US disclosed
US-20220354864-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA, INC. 2022-11-10 — — US disclosed
CN-109851617-B Chemical entities, compositions, and methods 润新生物公司 2022-08-16 — — CN disclosed
US-9550770-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2017-01-24 — — US disclosed
EP-3035936-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NeuPharma, Inc. (US) 2016-06-29 — — EP disclosed
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2015-06-25 — — US disclosed
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2015-06-25 — — US disclosed
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2015-06-25 — — US disclosed
WO-2015027222-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2015-02-26 — — WO disclosed
WO-2015027222-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2015-02-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170196881-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY DCK, ABL1, MAP4K2 EGFR 518/4885FGFR2 1364/4885FGFR1 1078/4885
US-20240197752-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY DCK, ABL1, MAP4K2 EGFR 518/4885FGFR2 1364/4885FGFR1 1078/4885
US-11865120-B2 Substituted quinazolines for inhibiting kinase activity DCK, ABL1, MAP4K2 EGFR 518/4885FGFR2 1364/4885FGFR1 1078/4885
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS BRAF, PIK3CA, PLK1 EGFR 272/4885FGFR2 365/4885FGFR1 441/4885
US-12403145-B2 Substituted quinazolines for inhibiting kinase activity DCK, ABL1, MAP4K2 EGFR 518/4885FGFR2 1364/4885FGFR1 1078/4885
US-20220354864-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY DCK, ABL1, MAP4K2 EGFR 518/4885FGFR2 1364/4885FGFR1 1078/4885
US-20260102406-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY BRAF, TTK, MAP4K2 EGFR 290/4885FGFR2 881/4885FGFR1 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.